Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors. (October 2020) - Macchini, M.; Garralda, E.; Fiedler, W.; Del Conte, G.; Rolling, C.; Kebenko, M.; Klinghammer, K.F.; Ahrens-fath, I.; Habel, B.; Baumeister, H.; Zurlo, A.; Ochsenreiter, S.